scanX
Home
Sun Pharmaceutical

Sun Pharmaceutical

1,683.60
-35.10
(-2.04%)
search
ann
Q4 Quarterly Results are out. Check out the updated financials1 day ago
Viewcross
right
Market Cap
4,03,952.00 Cr
EPS
39.90
PE Ratio
35.21
Dividend Yield
0.95 %
Industry
Healthcare
52 Week High
1,960.35
52 Week Low
1,377.20
PB Ratio
5.59
Debt to Equity
0.08
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from32 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+78.13 %
+78.13 %
Hold
Hold+12.50 %
+12.50 %
Sell
Sell+9.38 %
+9.38 %

Company News

View All News
Caret
neutral
Sun Pharma Targets Mid-to-High Single-Digit Revenue Growth for FY261 day ago
Sun Pharma has announced its revenue growth target for FY26, aiming for a mid-to-high single-digit increase. The company's guidance factors in regulatory uncertainties in the United States market.
neutral
Sun Pharmaceutical Industries Ltd: Targets Mid-To-High Single-Digit Growth for FY261 day ago
Sun Pharma aims for mid-to-high single-digit revenue growth in FY26, considering US regulatory uncertainties. The company awaits clarity on tariffs and MFN drug pricing policy impact. Halol facility is ready for FDA audit, while Mohali remediation is ongoing. Two new products, Leqselvi and Unloxcyt, are planned for FY26 launch. Specialty sales increased 17.1% YoY to $1.216 billion in FY25. US generics business faces competitive pricing environment.
positive
Sun Pharmaceutical Industries: $25M Investment in Pharmazz to Boost Stake to 22.7%1 day ago
Sun Pharma is investing up to $25 million in US-based Pharmazz Inc., increasing its stake to 22.7%. The investment supports development of two advanced drug candidates for stroke and shock. Sun Pharma gains options for licensing rights in certain markets. The company remains open to further acquisitions in specialty areas.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,683.60
#1 4,03,952.00
#6 35.21
#1 49,887.20
#7 12.06
#1 9,648
#10 -18.99
40.74
Divis Laboratories
6,483.00
1,72,103.30
78.53
8,184.00
0.89
1,600
23.05
63.44
Cipla
1,484.20
1,19,866.20
22.74
26,520.70
14.17
4,155
30.28
47.86
Torrent Pharmaceuticals
3,174.70
1,07,446.30
55.70
10,785.70
11.59
1,656
10.91
43.82
Dr Reddys Laboratories
1,230.10
1,02,646.40
#1 18.15
28,905.40
12.36
5,578
21.14
62.40
Mankind Pharma
2,432.40
1,00,355.60
50.56
10,615.60
19.57
1,942
-10.91
44.37
Zydus Life Science
908.60
91,426.40
19.56
19,831.50
13.82
3,831
-0.19
56.78
Lupin
1,978.90
90,344.90
27.54
20,141.50
#1 19.94
1,936
#1 112.49
44.10
Aurobindo Pharma
1,197.10
69,527.80
19.71
29,559.20
17.55
3,169
-10.04
50.83
Abbott
30,795.00
65,437.20
46.30
6,097.20
10.80
1,201
27.83
54.40

Automatic Screeners on ScanX

Community
Day 1 Unusual Volume
Community
1 Week Low Break
Forecast
Actual
Growth Rate
Revenue Growth
12.06 %
Net Income Growth
12.70 %
Cash Flow Change
144.69 %
ROE
-0.35 %
ROCE
5.02 %
EBITDA Margin (Avg.)
4.46 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
6,493
6,691
6,973
7,260
7,622
8,164
7,869
7,805
7,050
6,319
6,845
6,727
7,014
7,339
7,198
7,850
7,326
8,472
8,150
8,159
8,180
7,640
9,019
9,124
8,575
9,822
9,780
10,247
9,500
10,646
10,894
11,274
11,099
11,990
12,297
12,407
12,419
13,057
13,618
13,903
13,429
Expenses
5,318
5,679
5,000
4,877
5,382
5,335
5,092
5,472
5,590
6,064
5,275
5,200
5,294
5,618
6,621
5,587
6,147
6,379
6,334
6,314
7,083
9,375
6,360
6,431
7,147
7,529
6,996
7,257
11,042
7,877
7,996
8,237
8,300
8,932
9,013
8,974
9,049
9,045
9,352
9,983
9,604
EBITDA
1,175
1,012
1,973
2,383
2,240
2,829
2,776
2,333
1,460
255
1,570
1,528
1,720
1,721
577
2,263
1,179
2,094
1,816
1,845
1,098
-1,736
2,659
2,693
1,427
2,293
2,784
2,990
-1,542
2,769
2,899
3,037
2,799
3,058
3,284
3,433
3,370
4,012
4,266
3,920
3,824
Operating Profit %
13 %
13 %
27 %
31 %
27 %
33 %
34 %
29 %
18 %
2 %
20 %
21 %
21 %
21 %
3 %
27 %
13 %
23 %
20 %
21 %
12 %
-25 %
25 %
27 %
16 %
22 %
27 %
26 %
-18 %
26 %
26 %
26 %
23 %
24 %
25 %
26 %
23 %
28 %
29 %
26 %
25 %
Depreciation
462
240
258
251
288
316
304
307
338
347
359
339
455
402
427
471
454
457
473
547
575
496
499
532
554
503
530
554
557
588
610
660
672
651
633
622
650
655
626
631
664
Interest
135
135
158
128
103
135
54
167
45
109
157
95
155
131
130
145
150
104
84
63
52
52
33
26
30
35
36
19
37
14
19
46
93
81
49
35
74
62
69
52
49
Profit Before Tax
591
872
1,572
2,040
2,087
2,628
2,930
2,102
1,389
-159
1,114
1,148
1,376
1,274
112
1,730
694
1,647
1,433
1,351
577
-2,184
2,206
2,163
903
1,804
2,287
2,466
-2,076
2,285
2,412
2,472
2,240
2,481
2,791
3,000
2,816
3,424
3,598
3,476
3,254
Tax
-596
115
272
100
424
360
458
380
3
164
113
792
-187
88
272
269
-26
151
270
332
85
242
263
250
61
400
200
340
152
191
157
291
257
476
406
440
157
563
561
563
1,100
Net Profit
1,186
757
1,299
1,940
1,663
2,268
2,471
1,722
1,386
-323
1,002
356
1,563
1,186
-160
1,461
721
1,497
1,163
1,019
493
-2,426
1,943
1,913
842
1,404
2,086
2,126
-2,227
2,093
2,256
2,181
1,983
2,006
2,385
2,561
2,659
2,861
3,037
2,913
2,154
EPS in ₹
3.70
2.30
4.30
6.40
5.90
8.50
9.30
6.10
5.20
-1.77
3.80
1.34
5.60
4.41
-1.12
5.18
2.65
5.78
4.43
3.81
1.67
-6.90
7.56
7.72
3.70
6.00
8.50
8.60
-9.50
8.60
9.40
9.00
8.30
8.40
9.90
10.50
11.10
11.80
12.70
12.10
9.00
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
49,028
55,530
61,410
64,516
64,694
68,253
67,667
69,808
80,744
85,463
Fixed Assets
12,683
15,872
17,675
18,853
21,837
22,847
21,553
22,665
24,065
23,211
Current Assets
29,122
29,941
32,954
31,636
31,069
31,654
30,442
34,865
39,862
43,433
Capital Work in Progress
2,039
2,175
2,801
2,465
1,411
1,220
1,567
1,287
4,973
5,354
Investments
2,117
1,830
1,192
7,143
7,903
10,143
9,612
12,849
14,824
15,026
Other Assets
32,189
35,653
39,742
36,056
33,544
34,042
34,935
33,007
36,881
41,872
Total Liabilities
49,028
55,530
61,410
64,516
64,694
68,253
67,667
69,808
80,744
85,463
Current Liabilities
16,353
13,144
17,887
19,864
17,340
15,706
16,146
17,208
19,906
16,984
Non Current Liabilities
4,186
5,319
3,093
2,454
2,632
3,421
2,041
1,533
1,522
1,373
Total Equity
28,489
37,068
40,431
42,198
44,723
49,125
49,480
51,066
59,316
67,106
Reserve & Surplus
25,383
32,741
36,400
38,074
41,169
45,025
46,223
47,771
55,755
63,427
Share Capital
207
241
240
240
240
240
240
240
240
240
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
2,927
848
611
-736
-844
-1,386
596
-1,765
116
4,662
Investing Activities
-1,502
-3,949
-4,186
-3,104
-310
-2,225
407
-5,556
-7,220
-763
Operating Activities
5,616
6,686
7,082
3,907
2,196
6,555
6,170
8,985
4,959
12,135
Financing Activities
-1,187
-1,889
-2,285
-1,539
-2,731
-5,715
-5,981
-5,194
2,376
-6,710
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
16.79 %
0.00 %
17.72 %
17.23 %
18.02 %
18.05 %
17.96 %
DIIs
21.59 %
21.93 %
21.67 %
20.94 %
19.94 %
19.57 %
18.60 %
19.14 %
19.24 %
19.75 %
19.67 %
17.97 %
18.83 %
19.28 %
18.61 %
18.55 %
18.70 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
7.34 %
7.21 %
6.79 %
6.68 %
6.49 %
6.31 %
5.91 %
5.76 %
5.70 %
5.65 %
5.56 %
5.41 %
5.44 %
5.57 %
5.43 %
5.47 %
5.42 %
Others
16.60 %
16.38 %
17.05 %
17.90 %
19.09 %
19.64 %
21.01 %
20.63 %
20.58 %
20.12 %
3.51 %
22.13 %
3.53 %
3.44 %
3.46 %
3.46 %
3.45 %
No of Share Holders
0
7,09,045
7,57,366
6,75,908
6,80,800
6,62,384
6,47,167
6,43,512
6,25,252
6,24,561
6,16,588
6,12,626
6,31,392
6,73,217
6,57,317
6,89,623
7,04,983

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 3.5 2 2.75 4 7.5 10 11.5 13.5 0.00
Dividend Yield (%) 0.00 0.71 0.42 0.78 0.67 0.82 1.01 0.71 0.78 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
31 Jul 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 31 Jul 2025 1,731.60 1,683.25
22 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 22 May 2025 1,744.85 1,731.60
06 Feb 2025 DIVIDEND Dividend
₹ 10.50 /share
 06 Feb 2025 1,739.10 1,753.40
31 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 31 Jan 2025 1,756.85 1,739.10
21 Jan 2025 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
 21 Jan 2025 1,806.20 1,778.25
28 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 28 Oct 2024 1,916.85 1,860.40
05 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 05 Aug 2024 1,520.65 1,731.65
12 Jul 2024 DIVIDEND Dividend
₹ 5.00 /share
 12 Jul 2024 1,541.15 1,583.25
09 Feb 2024 DIVIDEND Dividend
₹ 8.50 /share
 09 Feb 2024 1,371.60 1,500.25
28 Jul 2023 DIVIDEND Dividend
₹ 4.00 /share
 28 Jul 2023 945.00 1,134.95
08 Feb 2023 DIVIDEND Dividend
₹ 7.50 /share
 08 Feb 2023 1,050.90 1,005.65
22 Aug 2022 DIVIDEND Dividend
₹ 3.00 /share
 19 Aug 2022 903.90 901.35
10 Feb 2022 DIVIDEND Dividend
₹ 7.00 /share
 09 Feb 2022 827.35 886.45
25 Aug 2021 DIVIDEND Dividend
₹ 2.00 /share
 23 Aug 2021 703.80 771.35
10 Feb 2021 DIVIDEND Dividend
₹ 5.50 /share
 09 Feb 2021 564.35 623.60

Announcements

Announcement under Regulation 30 (LODR)-Updates on Acquisition1 day ago
Investor Audio Call Recording2 days ago
Intimation Of Record Date For The Purpose Of Final Dividend2 days ago
Audited Financial Results For The Quarter And Year Ended 31 March 20252 days ago
Intimation Regarding Appointment Of Secretarial Auditor2 days ago
Corporate Action-Board approves Dividend2 days ago
Announcement under Regulation 30 (LODR)-Change in Directorate2 days ago
Board Meeting Outcome for Outcome Of Board Meeting2 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation4 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release8 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 12, 2025
Board Meeting Intimation for Approval Of Audited Financial Results For The Year Ended 31 March 2025 And Final Dividend If AnyMay 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 08, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 06, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 24, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 14, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Order Vacating Preliminary Injunction On LEQSELVI™Apr 10, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 07, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Apr 02, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateMar 31, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Mar 26, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Update On Our Investee CompanyMar 26, 2025
Closure of Trading WindowMar 25, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionMar 18, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Mar 11, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionMar 10, 2025
Announcement under Regulation 30 (LODR)-AcquisitionMar 10, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMar 04, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Mar 04, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 20, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Feb 18, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 17, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 07, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 06, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Regulatory OrderFeb 04, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Regulatory OrderFeb 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 04, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 04, 2025
Sustainability Report For The Financial Year 2023-24Feb 03, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Appointment Of Chief Operating OfficerFeb 03, 2025
Q3FY25 Investor Call Audio RecordingJan 31, 2025
Integrated Filing (Financial)Jan 31, 2025
Corporate Action-Board approves DividendJan 31, 2025
Outcome Of The Board Meeting Held Today I.E. January 31 2025Jan 31, 2025
Shareholder Meeting / Postal Ballot-Outcome of Court Convened MeetingJan 21, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 17, 2025
Intimation Under Regulation 42 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Revision In Record DateJan 16, 2025
Corporate Action-Board to consider DividendJan 16, 2025
Board Meeting Intimation for Approval Of Financial Results For Quarter And Nine Months Ended December 31 2024 And Interim DividendJan 16, 2025

Technical Indicators

RSI(14)
Neutral
40.74
ATR(14)
Volatile
48.21
STOCH(9,6)
Neutral
56.28
STOCH RSI(14)
Neutral
23.75
MACD(12,26)
Bearish
-8.59
ADX(14)
Weak Trend
16.60
UO(9)
Bearish
48.10
ROC(12)
Downtrend And Accelerating
-5.48
WillR(14)
Neutral
-70.63
Bearish
4
Neutral
5
Bullish
0

About Sun Pharmaceutical

Sun Pharmaceutical Industries Limited is a global specialty generic pharmaceutical company based in India. It manufactures and markets a wide range of pharmaceutical formulations including generics, branded generics, complex products, over-the-counter drugs, and active pharmaceutical ingredients. The company has a diverse portfolio covering multiple therapeutic areas and dosage forms. Sun Pharma has a strong presence in India and the US, which account for about 70% of its revenue. It operates 43 manufacturing facilities worldwide and invests 7-8% of revenue in R&D annually. The company has expanded through acquisitions and licensing deals to strengthen its specialty and generic portfolios. Key specialty products include Ilumya, Winlevi, Cequa and others in dermatology, ophthalmology and oncology. Sun Pharma supplies medicines to over 100 countries and has manufacturing facilities across six continents.
Website
https://www.sunpharma.com
Chairperson NameDilip S Shanghvi
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Intraday Screeners
Technical Screeners
Fundamental Screeners
Candlestick Screeners
Price & Volume Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Corporate Office: A-302, The Western Edge I, Off Western Express Highway, Borivali East, Mumbai – 400066, Maharashtra, India. Land Line: 022-43116666.